Your browser doesn't support javascript.
loading
Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.
Liu, Qingjie; Batt, Douglas G; Weigelt, Carolyn A; Yip, Shiuhang; Wu, Dauh-Rurng; Ruzanov, Max; Sack, John S; Wang, Jinhong; Yarde, Melissa; Li, Sha; Shuster, David J; Xie, Jenny H; Sherry, Tara; Obermeier, Mary T; Fura, Aberra; Stefanski, Kevin; Cornelius, Georgia; Khandelwal, Purnima; Tino, Joseph A; Macor, John E; Salter-Cid, Luisa; Denton, Rex; Zhao, Qihong; Dhar, T G Murali.
Afiliação
  • Liu Q; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Batt DG; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Weigelt CA; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Yip S; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Wu DR; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Ruzanov M; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Sack JS; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Wang J; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Yarde M; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Li S; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Shuster DJ; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Xie JH; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Sherry T; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Obermeier MT; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Fura A; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Stefanski K; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Cornelius G; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Khandelwal P; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Tino JA; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Macor JE; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Salter-Cid L; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Denton R; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Zhao Q; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
  • Dhar TGM; Research and Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08540-4000, United States.
ACS Med Chem Lett ; 11(12): 2510-2518, 2020 Dec 10.
Article em En | MEDLINE | ID: mdl-33335675
ABSTRACT
Employing a virtual screening approach, we identified the pyroglutamide moiety as a nonacid replacement for the cyclohexanecarboxylic acid group which, when coupled to our previously reported conformationally locked tricyclic core, provided potent and selective RORγt inverse agonists. Structure-activity relationship optimization of the pyroglutamide moiety led to the identification of compound 18 as a potent and selective RORγt inverse agonist, albeit with poor aqueous solubility. We took advantage of the tertiary carbinol group in 18 to synthesize a phosphate prodrug, which provided good solubility, excellent exposures in mouse PK studies, and significant efficacy in a mouse model of psoriasis.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
...